Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

25,526 signal articles · 28 in last 24h · 122,310 total before filter · latest 1h ago
28last 24h
1249last 7d
210● bullish (7d)
150● bearish (7d)
205publishers
AllMacro211Earnings429M&A97Regulatory24Product9Analyst10
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
SpaceX (SPCX) Stock Faces Lockups And Index Buying After Wild IPO Debut
Simply Wall St.49d agobullish
SpaceX (SPCX) Stock Faces Lockups And Index Buying After Wild IPO Debut

Space Exploration Technologies (NasdaqGS:SPCX) has seen unprecedented volatility following its IPO, with sharp swings in the share price. Upcoming lockup expirations are set to release substantial insider holdings into the market over the next few months. Potential inclusion in the Nasdaq-100 index and related ETFs could trigger short term buying activity in SPCX shares. Heavy capital expenditures, a recent debt offering, a high P/S multiple and reliance on Starlink profits are drawing...

Trump’s FDA May Soon Throw Its Weight Behind Peptides. Should You Buy In?
Barrons.com49d agobullish
Trump’s FDA May Soon Throw Its Weight Behind Peptides. Should You Buy In?

Peptides are short-chain amino acids that are formulated into drugs. Insulin is a peptide. Legions of other peptides are on the market in the “wellness” industry, promoted for everything from athletic performance to skin care, mental focus, and “romantic connection”—the latter pitched by a startup called Feel Peptides.

Goldman Sachs doubles down on Robinhood stock after record trading surge
TheStreet49d agobullish
Goldman Sachs doubles down on Robinhood stock after record trading surge

Robinhood has spent the last year adding businesses at a pace few brokerages can match. Prediction markets, banking, an AI trading assistant, and a new credit card all launched within months of each other. Now Wall Street is starting to price in what that expansion means for the bottom line. ...

Jim Cramer makes bold buy call on one booming energy stock
TheStreet49d agobullish
Jim Cramer makes bold buy call on one booming energy stock

When Jim Cramer says a stock is his favorite in a category and mentions it sits in his Charitable Trust as a "very big position," that is not a casual endorsement. Rather, it's a declaration of conviction. On Mad Money's Lightning Round on June 30, a caller asked about GE Vernova (GEV). Cramer did ...

Babcock & Wilcox (BW) Looks Poised to Jump More Than 50%, Here is Why
Insider Monkey49d agobullish
Babcock & Wilcox (BW) Looks Poised to Jump More Than 50%, Here is Why

Babcock & Wilcox Enterprises Inc. (NYSE:BW) is one of the 12 best industrial stocks with more than 50% upside. On June 8, Babcock & Wilcox Enterprises Inc. (NYSE:BW) shared that it has formed an alliance with TerraSpark regarding its scheduled energy project based in West Virginia. The project is referred to as the TerraSpark Energy […]

Here is Why Planet Labs (PL) is One of the Best Industrial Stocks to Buy
Insider Monkey49d agobullish
Here is Why Planet Labs (PL) is One of the Best Industrial Stocks to Buy

Planet Labs PBC (NYSE:PL) is one of the 12 best industrial stocks with more than 50% upside. On June 11, Goldman Sachs increased the firm’s target price on Planet Labs PBC (NYSE:PL) from $20 to $22, and maintained a Neutral rating on the stock. The firm noted that, based on impressive growth across defense and […]

Cathie Wood buys $38.1 million of tumbling megacap stock
TheStreet49d agobullish
Cathie Wood buys $38.1 million of tumbling megacap stock

Cathie Wood, chief of Ark Investment Management, is known for buying “disruptive” tech stocks during market pullbacks. That’s what she just did, adding one of her highest-conviction investments, Tesla, as the stock fell more than 7% in a day. In 2025, the flagship Ark Innovation ETF gained 35.49%, ...

Merck (MRK) Wins New KEYTRUDA Approvals As Tulisokibart Clears A Phase 3 Test
Simply Wall St.49d agobullish
Merck (MRK) Wins New KEYTRUDA Approvals As Tulisokibart Clears A Phase 3 Test

Merck (NYSE:MRK) reported positive Phase 3 results for tulisokibart, an anti-TL1A monoclonal antibody in moderate-to-severe ulcerative colitis. The company announced new FDA approvals for KEYTRUDA-based regimens in triple-negative breast cancer and muscle-invasive bladder cancer. Regulatory authorities in the EU also cleared additional KEYTRUDA combinations in early-stage oncology settings. For investors tracking NYSE:MRK, these updates sit at the core of what drives long term value for a...

Jim Cramer says it's time to buy one surging space stock
TheStreet49d agobullish
Jim Cramer says it's time to buy one surging space stock

As America celebrates its 250th birthday this July 4 weekend, Jim Cramer took a moment on the "Mad Money" Lightning Round Tuesday, June 30, to flag a space company he believes could make investors real money over the next two years. The stock is AST SpaceMobile (ASTS). The call was brief, as ...

Why GPIQ Lags QQQ in Rallies, Yet Retirees Keep Buying the Monthly Dividend
24/7 Wall St.49d agobullish
Why GPIQ Lags QQQ in Rallies, Yet Retirees Keep Buying the Monthly Dividend

The Goldman Sachs Nasdaq-100 Premium Income ETF (NASDAQ:GPIQ) has become one of the fastest-growing options-income products on the market, pulling in roughly $2.12 billion of net inflows in 2025 on the strength of a distribution yield that recently sat near 9.8% to 10%. GPIQ investors are buying a monthly paycheck backed by call premiums on ... Why GPIQ Lags QQQ in Rallies, Yet Retirees Keep Buying the Monthly Dividend

Is Lockheed Martin (LMT) Still Trading At A Discount After Contract Wins?
Simply Wall St.49d agobullish
Is Lockheed Martin (LMT) Still Trading At A Discount After Contract Wins?

Lockheed Martin stock has returned 63.1% over the past five years, and today the valuation checks suggest the market price may still sit below an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach. Over 5 years, a 63.1% total return indicates Lockheed Martin has already rewarded patient shareholders, so any valuation upside now matters more for fresh capital. Recent contract wins and acquisition plans can support expectations for future defense cash flows. At the same...